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T cells in chronic viral infections are featured by premature aging with accelerated
telomere erosion, but the mechanisms underlying telomere attrition remain unclear. Here,
we employed human CD4T cells treated with KML001 (a telomere-targeting drug) as
a model to investigate the role of telomere integrity in remodeling T cell senescence.
We demonstrated that KML001 could inhibit cell proliferation, cytokine production,
and promote apoptosis via disrupting telomere integrity and DNA repair machineries.
Specifically, KML001-treated T cells increased dysfunctional telomere-induced foci
(TIF), DNA damage marker γH2AX, and topoisomerase cleavage complex (TOPcc)
accumulation, leading to telomere attrition. Mechanistically, KML001 compromised
telomere integrity by inhibiting telomeric repeat binding factor 2 (TRF2), telomerase,
topoisomerase I and II alpha (Top1/2a), and ataxia telangiectasia mutated (ATM)
kinase activities. Importantly, these KML001-induced telomeric DNA damage and T cell
senescent phenotype and machineries recapitulated our findings in patients with clinical
HCV or HIV infection in that their T cells were also senescent with short telomeres and
thus more vulnerable to KML001-induced apoptosis. These results shed new insights
on the T cell aging network that is critical and essential in protecting chromosomal
telomeres from unwanted DNA damage and securing T cell survival during cell crisis
upon genomic insult.
Keywords: aging, apoptosis, DNA damage repair, KML001, telomeres, T cells, HCV, HIV
INTRODUCTION
T cells play a crucial role in defending the host against infections; however, the mechanisms
controlling their responses to pathogenic infections remain incompletely understood. In studying
the role of T cell dysfunctions in viral persistence, we and others have previously shown that
chronic viral (HCV and/or HIV) infections can induce premature T cell aging and immune
senescence, as evidenced by the overexpression of aging markers (such as p16ink4a, p21cip1, CD57,
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and KLRG1), dysregulation of aging-associated microRNAs
(miR181/miR21), and particularly, accelerated erosion of
telomeres, suggesting excessive cell proliferative turnover,
or inadequate telomere maintenance (1–13). Telomeres are
repeating hexameric DNA sequences (TTAGGG) that are
found at the chromosome ends in association with a complex
of shelterin proteins (14). Telomere integrity is a key feature
of linear chromosomes that preserves genome stability.
Conversely, telomere erosion is a hallmark of cell senescence (a
quiescent, non-replicative state) that drives cell dysfunction or
apoptosis (15–17).
Human T cell telomeres normally shorten at a rate of 50∼100
base pairs per cell division, acting as a molecular clock to
control the replicative capacity before entering cell senescence
or apoptosis (17). However, telomere loss can increase up to
250 bp per cell cycle during chronic viral infection and, in
compensating for this, cell cycle arrest occurs when progressive
telomere loss reaches a critical point, a phenomenon known
as replicative senescence (17, 18). While telomere length is
maintained in most cases by an enzyme called telomerase, the
telomeric shelterin complex is required to protect telomeres
from the undesired DNA damage response (DDR) (16–19).
The capping roles of this shelterin complex are to inhibit
DDR pathways at telomeres, regulate telomerase access and
functions, prevent telomeric DNA from degradation or erosion,
and thus safeguard human chromosome ends (19). Among
the many mammalian telomeric shelterin proteins identified
in the past decade, telomeric repeat binding factor 2 (TRF2)
plays a crucial role in protecting chromosome ends against
instability (20, 21). TRF2 binds specifically to double-stranded
telomeric sequences and remodels the telomeric DNA into a t-
loop structure that is essential in protecting chromosome ends via
suppressing the ataxia telangiectasia-mutated (ATM) kinase and
p53-dependent DDR and non-homologous end joining (NHEJ)
pathways (19, 20). In addition to its DNA capping role, TRF2
also recruits a number of proteins and enzymes required for
protecting telomeric sequences against replicative DNA damages,
including Apollo and topoisomerases I and IIα (Top1/2α) under
topological stress (22). Notably, TRF2 expression is increased at
the RNA and protein levels in a variety of human cancer cells, and
its down-regulation reduces tumorigenicity (23–25). However,
the role and mechanisms of TRF2, telomerase, Top1/2α, and
ATM in telomeric DNA damage and repair in T lymphocyte
senescence remain elusive.
Arsenic is a ubiquitous contaminant that is considered one of
the top environmental health threats because of the population’s
potential exposure from contaminated drinking water and the
high number of diseases associated with it, including cancer (26,
27). Arsenic is not considered a direct carcinogen; nevertheless,
it may increase DNA damage and mutation indirectly by
altering DNA repair machinery (28, 29). Recent studies have
demonstrated that arsenic is also an immunotoxic agent,
although the mechanisms for its cytotoxic effects remain largely
unknown (30, 31). Evidence has shown that arsenic binds
to telomeric DNA sequences, causing telomere attrition (32,
33). Arsenic can also induce reactive oxygen species (ROS)
production, causing chromosome instability, and aberration (34,
35). On the other hand, as traditional medicine has claimed that
“toxin = medicine” for centuries, arsenic compounds have been
used as a treatment modality. KML001 [sodium (meta)arsenite,
NaAsO2] is a telomere-targeting, orally bio-available arsenic
compound with potential anti-cancer activity (32, 33).
In this study, we used KML001 as a telomere targeting agent in
CD4T cells derived from healthy subjects (HS) and chronically
virus (HCV, HIV)-infected individuals to investigate the role of
telomere integrity and DNA repair machineries in remodeling
T cell senescence. We demonstrated that KML001 could induce
telomeric DNA damage and T cell apoptosis via inhibiting TRF2,
telomerase, Top1/2a, and ATM activities, similar to what we
have seen in T cells during chronic viral (HCV, HIV) infection.
These studies shed new light on the T cell aging network,
which is important for developing novel approaches in protecting
telomere integrity in T cells against chronic infectious diseases.
MATERIALS AND METHODS
Subjects
The study protocol was approved by the institutional review
board (IRB) of East Tennessee State University and James H.
Quillen VA Medical Center (ETSU/VA IRB, Johnson City, TN).
Written informed consent was obtained from all participants.
The study subjects were composed of three populations: 26
chronically HCV-infected individuals prior to antiviral therapy,
21 latently HIV-infected individuals on antiretroviral therapy
(ART) with undetectable viremia, and 64 age-matched healthy
subjects (HS). Blood samples of HS, derived from Physicians
Plasma Alliance (PPA), Gray, TN, were negative for HBV, HCV,
and HIV infection. The characteristics of the participants in this
study was summarized in Table 1.
Cell Isolation and Culture
PBMCs were isolated from whole blood by Ficoll (GE
Heathcare, Piscataway, NJ) density centrifugation. CD4+ T
cells were isolated from PBMCs using the CD4+ T Cell
Negative Isolation Kit and a MidiMACSTM Separator (Miltenyi
Biotec Inc., Auburn, CA). The isolated CD4T cells were
cultured in RPMI 1640 medium containing 10% FBS (Atlanta
Biologicals, Flowery Branch, GA), 100 IU/ml penicillin and
2mM L-glutamine (Thermo Scientific, Logan, Utah) with
varying concentrations of KML001 (Sigma) or DPBS (Dulbecco’s





Viral load and genotypes
HCV 26 28–66 (49) 17/9 54,120 ∼ 14,466,174 IU/ml, 17
GT1, 5 GT2, 4 GT3
HIV 21 28–61 (46) 15/6 All on ART with undetectable
HIV-RNA
HS 64 23–65 (47) 41/23 All tested negative for HCV, HBV,
and HIV
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Phosphate-Buffered Saline) control for different times at 37◦C
and 5% CO2 atmosphere.
Flow Cytometry
For CD4T cell proliferation, the cells were labeled with CFSE and
cultured in the presence of anti-CD3 (1µg/ml)+CD28 (2µg/ml,
BD Bioscience) for 3 days, followed by flow cytometry analysis for
measuring CFSE dilution in dividing cells as described previously
(3). To quantify cell apoptosis, PBMCs or T cells were isolated,
cultured in the presence or absence of KML001 and 10 µg/ml
mouse anti-human CD178 (a-Fas ligand), CD40 (a-TNFα), and
CD253 (a-TRAIL) or mouse IgG1 κ isotype control antibody
(BD Biosciences, San Jose, CA) and collected at the indicated
times, and then stained with CD4-FITC (eBioscience), Annexin
V, and 7-AAD using BD PharmingenTM PE Annexin V Apoptosis
Detection Kit I (BD Biosciences). For intracellular staining, the
cells were stimulated with or without 50 ng/ml PMA + 1µg/ml
Inonomycin (Sigma) and 1µg/ml Brefeildin A (Biolegend)
4 h before harvesting, fixed and permeabilized with Foxp3
Transcription Factor Staining Buffer Set (eBioscience, San Diego,
CA), and then stained with CD4-APC, IL-2-FITC (Biolegend),
and IFN-γ-PE (eBioscience), TRF2-PE, or γH2AX (eBioscience).
The stained cells were analyzed on AccuriTM C6 flow cytometer
(BD Bioscience. Franklin Lakes, NJ) and the data were analyzed
by FlowJo software (Tree Star, Inc., Ashland, OR). Isotype control
antibodies (eBioscience) and fluorescence minus one (FMO)
controls were used to determine the background levels of staining
and adjust multicolor compensation as gating strategy.
Telomere Length and Telomerase Activity
Telomere length of CD4+ T cells was measured using flow-
FISH (florescence in-situ hybridization) protocol as described
previously (4). Briefly, CD4+ T cells were treated with 5µM
KML001 or DPBS control for 3∼5 days, and then stained with
CD4-CY5 (Southern Biotech, Birmingham, AL). After fixation
and permeabilization, the cells were incubated in hybridization
buffer with 0.5µM of FITC-PNA Tel C probe (CCCTAAC
repeats) (PNA Bio, Thousand Oaks, CA) for 10min at RT.
Samples were heated for 10min at 85◦C, rapidly cooled on ice,
and hybridized at RT in the dark overnight. Samples were washed
and analyzed immediately by flow cytometry, and lymphocyte
telomere length was shown as mean fluorescence intensity (MFI).
Telomeric Repeat Amplification Protocol (TRAP) assay
was employed to measure telomerase activity of CD4T
cells using the TRAPEZE R© RT Telomerase Detection Kit
(EMD Millipore, Billerica, MA) following the manufacturer’s
instruction. Approximately 1 × 106 CD4T cells were purified
and treated by KML001 as described above, harvested and
lysed in 100 ul CHAPS buffer, incubated on ice for 30min,
and centrifuged at 12,000 g and 4◦C for 20min. About 400
ng cells lysate was applied for TRAP assay. Each sample was
accompanied by two negative controls (10min heated at 85◦C
or with an inhibitor). Standard curves were built on the TSR8
control template with a range of 0.04 ∼ 40 amoles. About 400
ng lysate from telomerase positive cells was used as positive
control. Samples were run in triplicate using the following PCR
cycle conditions: 1 cycle at 30◦C for 30min and 95◦C for 2min,
followed by 45 cycles at 94◦C for 15 s, 59◦C for 60 s and 45◦C
for 10 s. Data were analyzed and quantitated by CFX ManagerTM
Software (Bio-Rad).
RNA Isolation and Real-Time RT-PCR
Total RNAwas extracted from 1.0× 106 cells with PureLink RNA
Mini Kit (Invitrogen, Carlsbad, CA), and cDNA was synthesized
using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems; Foster City, CA) per the manufacturer’s
instruction. Quantitative PCR were run in triplicates using the
following conditions: 95◦C, 10min and then 95◦C, 15 s; 60◦C,
60 s with 40 cycles. Gene expression was normalized to GAPDH
and expressed as fold changes using the 2−11ct method. Primer
sequences are shown in Table 2.
Western Blotting
Naïve CD4T cells were treated with 5µM KML001 or DPBS
control for 48 h. The cells were harvested and lysed on ice in RIPA
buffer (Boston BioProducts Inc, Ashland, MA) in the presence
of protease inhibitors (Thermo Scientific, Rockford, IL). The
protein concentrations were measured by Pierce BCA protein
assay kit (Thermo Scientific). The proteins were separated by
SDS-PAGE, transferred to polyvinylidene difluoride membranes,
pre-blocked with 5% non-fat milk, 0.1% Tween-20 in Tris
buffered saline (TBS), and incubated with the following primary
antibodies: PARP1, TRF1, TRF2, POT1, TIN2, RAP1, TPP1, P53,
ATM, pATM, Top1, Top2a, Apollo, MRE11, RAD50, NBS1, or
Sirt6. The membranes were reprobed with β-Actin antibody (Cell
Signaling, Danvers, MA) as a loading control. P24 antibody was
obtained from NIH/NIAID AIDS reagent program. Appropriate
horseradish peroxide-conjugated secondary antibodies (Cell
Signaling) were used, and the proteins were detected using
Amersham ECL Prime Western Blotting Detection Reagent (GE
Healthcare Bio-Sciences, Pittsburgh, PA). Protein bands were


















HIV RNA 5′-CAGATCCTGCATATAAGCAGCTG-3′ 5′-TTTTTTTTTTTTTTTTTT
TTTTTTGAAGCAC-3′
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captured and quantified using the Chemi DocTM MP Imaging
System (Bio-Rad System).
TOP1cc Detection
TOP1cc was detected using the Human Topoisomerase ICE
Assay Kit (Topogen, Inc., Cal No: TG1020-1, Buena Vista, CO
81211). Method of DNA purification was modified by combining
ICE Assay Kit and PureLinkTM Genomic DNAMini Kit (Thermo
Fisher Scientific, Catalog number: K182001, Waltham, MA
02451). Briefly, genomic DNA sample were extracted from cell
pellets using the buffers of ICE assay kit and then purified by
the column of PureLinkTM Genomic DNA Mini Kit. The DNA
samples were loaded to NC membrane by a vacuum pump,
and were incubated with primary anti-TOP1cc antibody from
ICE assay kit, a monoclonal antibody that specifically recognizes
covalent TOP1-DNA complexes but not free Top 1 or DNA,
followed by western blot procedure as described.
Confocal Microscopy
CD4+ T cells were isolated and cultured as described above.
The cells were fixed in 2% PFA for 20min, permeabilized with
0.3% Triton X-100 in PBS for 10min, blocked with 5% BSA in
PBS for 1 h, and then incubated with rabbit anti-53BP1, anti-
Ku70, anti-RAD51, or anti-TOP1cc antibody and mouse anti-
TRF1 antibody (Cell Signaling) at 4◦C overnight. The cells were
washed three times with PBS with 0.1% Tween-20, stained with
anti-rabbit IgG-Alexa Fluor 488 and anti-mouse IgG- Alexa
Fluor 555 (Invitrogen) antibodies at room temperature for 1 h,
and then washed and mounted with DAPI Fluoromount-G
(SouthernBiotech, Birmingham, AL). Images were acquired with
a confocal laser-scanning inverted microscope (Leica Confocal,
Model TCS sp8, Germany).
CD4T Cells Co-culture With Huh-7.5 Cells
With or Without HCV Transfection
Huh-7.5 cells were transfected with or without HCV JFH1 strain
for 48 h. The HCV core protein was detected by fluorescence
microscopy as described previously (36). Purified naïve CD4T
cells were co-cultured with Huh7.5 cells with or without HCV
infection for 48 h. The CD4T cells were harvested and TRF2
expression was determined by western blotting.
HIV-1 Plasmid Transfection and Virus
Infection
The pNL4-3 plasmid, which contains a full-length HIV-1 viral
DNA inserted in pUC18 vector, was obtained from NIH AIDS
Reagent Program. About 20 µg of the HIV-1 plasmid was used
for the transfection of HEK293T cells using the polyethylenimine
(PEI) method (37). The supernatants of HIV-1-transfected 293T
cells were used to infect human Sup-T1 cells (obtained from
an individual with Non-Hodgkin’s T cell lymphoma; NIH AIDS
Reagent Program) using the spinoculation method (37). Briefly,
1.5× 106 Sup-T1 cells were infected with supernatant containing
1∼5× 106 HIV-1 in culture plates using centrifugation at 1,620×
g in a 37◦C incubator. After 2 h of spinoculation, the supernatants
were removed to get rid of the unattached viruses. Cells were
harvested at the indicated times, and used for RT-PCR and
western blot analyses.
Statistical Analysis
The data were analyzed using Prism 7 software, and are
summarized as mean± SEM or median with interquartile range.
Comparisons between two groups were made using independent
Student’s t-test, or paired T test. Multiple comparisons
were made using test/least significant difference or Tukey’s
procedure, depending on the ANOVA F test or by a non-
parametric Mann–Whitney U-test. P-values <0.05, <0.01,
or <0.001 were considered statistically significant or very
significant, respectively.
RESULTS
KML001 Inhibits Human CD4T Cell
Proliferation, Cytokine Production, and
Induces Apoptosis
Environmental exposure of human populations to arsenic from
contaminated drinking water has been associated with a high
incidence of detrimental diseases, likely due to its immunotoxic
and genotoxic effects (25–35). As a first step to study its effects
on the human immune system, we employed arsenic KML001—
a telomere-targeting drug—as a tool by culturing healthy PBMCs
in the presence or absence of anti-CD3/CD28 (1µg/ml each)
stimulation and varying concentrations of KML001 for different
times, followed by measuring T cell proliferation, cytokine
production, and apoptosis by flow cytometry. As shown in
Figure 1A, TCR-stimulated CD4T cells exhibited better cell
division (measured by CFSE dilution) when cultured for 3
days in the absence of KML001 (red line), moderate cell
division at low dose (1µM) of KML001 (blue line), and no
cell division in the presence of high dose (5µM) of KML001
(orange line), indicating a dose-dependent inhibition of T
cell proliferation by this telomere-targeting drug. Also, the
intracellular IL-2 (Figure 1B, P < 0.0001) and IFN-γ (Figure 1C,
P = 0.0022) cytokine productions in TCR-stimulated CD4T
cells were significantly inhibited by KML001 treatment for 48 h.
Moreover, PBMCs exposed to KML001 showed dose- and time-
dependent increases in CD4T cell apoptotic death compared
to the untreated controls (Figure 1D). These data suggest that
KML001 inhibits T cell proliferation, cytokine production, and
promotes cell apoptotic death.
KML001-Induced T Cell Apoptosis Is
Independent Upon the Extrinsic Death
Pathways
The mechanisms underlying KML001 induction of T cell
apoptosis remain unclear. Interactions between Fas-Fas ligand,
TNFα-TNF receptor, and TRAIL-TRAIL receptor have been
shown to play an important role in cell apoptosis in response to
exogenous or endogenous stimulations. Notably, we and others
have previously shown that in chronic viral or inflammatory
diseases, the problem of T cell homeostasis is primarily vested
in naïve T cell loss; however, resting naïve T cells usually do
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FIGURE 1 | KML001 inhibits CD4T cell proliferation, cytokine production, and induces apoptotic death. Healthy PBMCs were cultured in the presence or absence of
TCR stimulation and varying concentrations of KML001 for different times, followed by measuring T cell proliferation, cytokine production, and apoptosis by flow
cytometry. (A) KML001 inhibits CD4T cell proliferation in a dose-dependent manner, measured by CFSE dilution in dividing cells. (B,C) KML001 inhibits IL-2 and
IFN-γ productions in TCR-stimulated CD4T cells. Representative dot plots and summary data from 8 subjects per group are shown. (D) KML001 promotes CD4T
apoptotic death, in a dose- and time-dependent manner, determined by the percentage of Av/7AAD positive cells.
not express these receptors on their cell surface to initiate
programmed cell death (Figure 2A) (36, 38, 39).
To determine whether KML001-induced T cell apoptosis is
dependent upon the extrinsic death pathways, we incubated
purified CD4T cells with or without 5µM KML001 in the
presence of blocking antibodies for Fas-ligand (10 µg/ml
anti-human CD178), TNFα (10µg/ml anti-human CD40), and
TRAIL (10µg/ml anti-human CD253), or IgG1 κ isotype
control antibody (BD) for 48 h, followed by Av/7AAD assay
to determine cell apoptosis. As shown in Figure 2B, compared
to the controls (Control + Isotype), CD4T cells incubated
with the blocking antibody alone in the absence of KML001
(upper panel) did not exhibit any change in cell apoptosis and
death. KML001 treatment (KML001 + Isotype) increased T
cell apoptosis and death; however, adding blocking antibody
into the culture (lower panel) did not abrogate the KML001-
induced T cell apoptosis and death. Additionally, we added
all three blocking antibodies simultaneously into the cultures
and did not observe any antagonistic effect on KML001-
induced T cell apoptosis and death (Figure 2C), although
these blocking antibodies slightly diminished the KML001-
induced cell apoptosis in cultured PBMCs (Figure 2D), which
include NKs, B cells, and monocytes/macrophages that may
have respective ligand/receptor expressions on their cell surfaces.
We were able to reproduce these results using CD4T cells
or PBMCs isolated from different subjects. Taken together,
these results suggest that blocking the extrinsic death pathways
by disrupting the Fas-Fas ligand, TNFα-TNFγ, and TRAIL-
TRAILγ interactions in cultured CD4T cells does not affect
KML001-mediated cell apoptotic death. This is in line with
the reports showing that naïve CD4T cells are resistant to
exogenous apoptotic pathway-mediated cell death, but sensitive
to endogenous oxidative stress, being particularly vulnerable to
ROS-mediated genotoxicity (36, 38–40).
KML001 Induces T Cell Apoptotic Death
Through the Telomeric DNA Damage
Response (DDR)
How KML001 triggers T cell apoptosis is unclear. Previous
studies have shown that KML001 can directly bind to telomeric
DNA sequences and cause cytotoxicity by inducing telomere
erosion in cancer cells (32). To investigate whether KML001
triggers T cell apoptosis via telomeric DNA damage or
telomere erosion, we examined DNA damage markers and
telomere length in CD4T cells exposed to it. We chose to
study caspase-dependent pathways as they are the central
components of the apoptotic response. Caspases are usually
produced in cells as catalytically inactive zymogenes and must
undergo proteolytic activation before entering the apoptotic
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FIGURE 2 | KML001-induced CD4T cell apoptosis is independent of the extrinsic death pathways. (A) CD95 (Fas receptor) expression on resting naïve CD4T cells,
measured by flow cytometic analysis. (B) Purified CD4T cells were cultured with or without 5µM KML001 in the presence of blocking antibodies for Fas ligand (10
µg/ml), TNFα (10 µg/ml), and TRAIL (10 µg/ml), or IgG1 κ isotype control for 48 h, followed by Av/7AAD assay to determine cell apoptosis. (C) Purified CD4T cells
were cultured with or without 5µM KML001 in the presence of all three blocking antibodies, followed by Av/7AAD assay. (D) PBMCs were cultured with or without
5µM KML001 in the presence of all three blocking antibodies or isotype control, followed by Av/7AAD assay.
cascade (41). For example, caspase-3 is frequently activated
by death proteases to catalyze the specific cleavage of cellular
proteins including Poly ADP-Ribose Polymerase 1 (PARP1),
an enzyme that catalyzes the transfer of ADP-ribose onto
target proteins that plays an important role in maintaining
DNA damage repair and chromosomal stability (41). Therefore,
to determine whether KML001-induced T cell apoptosis is
mediated by triggering telomeric DDR, we measured the total
and cleaved form of PARP1 in KML001-treated CD4T cells by
western blotting and found that the total level of PARP1 was
significantly decreased, whereas its cleaved form was significantly
increased, in CD4T cells treated with 5µM KML001 for
48 h (Figure 3A). This data clearly reveals a DNA damage-
triggered, capspase-3-dependent T cell apoptosis induced by the
KML001 treatment.
Following genomic insults, histone variant H2AX is
phosphorylated (S139) at the site of DNA double strand
breaks (DSB) to form γH2AX that subsequently recruits other
DNA damage and repair proteins to trigger DDR. To further
assess telomeric DDR as a possible cause of impaired T cell
survival, CD4T cells were purified from HS, treated with 5µM
KML001 for 48 h, followed by flow cytometric analysis of
γH2AX, a marker for DNA damage. As shown in Figure 3B,
γH2AX expression was remarkably increased in the CD4T cells
exposed to KML001.
In conjunction with H2AX phosphorylation, 53BP1 is
recruited to the DNA damage site (including telomeric break
vicinity) and acts as a docking site for other adaptor proteins to
form microscopically visible nuclear focus (DNA damage foci).
Thus, identifying dysfunctional telomere-induced foci (TIF) is
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FIGURE 3 | KML001 triggers telomeric DDR and causes telomere attrition in CD4T cells. (A) Purified CD4T cells from HS were treated with 5µM KML001 or DPBS
control for 48 h, followed by western blotting to measure total and cleaved PARP1 levels. (B) KML001 induces γH2AX expression in CD4T cells exposed to 5µM
KML001 for 48 h, followed by flow cytometry analysis. (C) KML001 increases dysfunctional telomere-induced foci (TIF). Purified CD4T cells were treated with 5µM
KML001 or DPBS control for 48 h, followed by confocal microscopy examination to assess co-localization of 53BP1 and TRF1. Approximately 100 cells were
counted, and representative imaging and summary data of the TIF numbers per nucleus and the percent of cells with ≥ 3 TIFs are shown. (D) Purified CD4T cells
were treated with 5µM KML001 or DPBS control for 5 days, followed by Flow-FISH analysis to determine telomere lengths. Representative overlaid histograms and
summary data are shown. (E) Purified CD4T cells were treated with 5µM KML001 or DPBS control for 48 h, followed by real-time RT-PCR to measure hTERT (the
catalytic unit of telomerase) mRNA levels. (F) Telomerase activity in CD4T cells treated with 5µM KML001 or DPBS control for 48 h, followed by TRAP assay. The
number of subjects to be examined and the p-value of statistical analysis is shown in all summary data.
typically deemed as a hallmark of telomeric DDR (42, 43).
To confirm telomeric DNA damage in CD4T cells exposed to
KML001, we compared numbers of TIFs per nucleus and the
percent of cells with > 3 TIFs by examining co-localization
of 53BP1 with telomere-associated shelterin protein TRF1 by
confocal microscopy. As shown in Figure 3C, the representative
imaging and summary data of confocal microscopy, the numbers
of 53BP1/TRF1 TIF per nucleus and the percentage of T cells
with > 3 TIFs were significantly higher in CD4T cells treated
with KML001 for 48 h (P = 0.0013, P = 0.0004, respectively).
These data indicate that KML001-treated CD4T cells exhibit
DNA damage that extends to the chromosome ends—telomeres.
KML001 Induces Telomere Erosion by
Inhibiting Telomerase Activity
Telomere erosion is a hallmark of cell senescence that leads to
cell dysfunction or apoptosis (15–17). To demonstrate whether
KML001-treated human CD4T cells have telomere erosions,
we measured telomere length by Flow-FISH. As shown in
Figure 3D, purified human CD4T cells treated with 5µM
KML001 for 3 days exhibited a significantly shortened telomere
length compared to theDPBS-treated control (P= 0.0036). These
results recapitulate the findings by us in patients with chronic
viral (HCV, HIV) infection in that their T cells are senescent,
characterized by the significant telomere loss (4, 38).
Because of the inability of conventional DNA polymerase to
replicate the 3′-end telomeric overhang, telomere sequences are
replenished by telomerase, which is composed of telomerase RNA
(TR) and human telomerase reverse transcriptase (hTERT)—
the catalytic unit of telomerase (44). Since the primary function
of telomerase is to prolong telomeric DNA sequences, we
hypothesized that T cell telomere shortening is likely a result
of telomerase inhibition by KML001. To test this possibility, we
measured hTERT transcript copies in purified CD4T cells treated
with 5µM KML001 or DPBS for 48 h using real-time RT-PCR.
Unexpectedly, no significant differences (P= 0.2361) were found
in hTERT expression levels in T cells exposed to KML001 or
DPBS control (Figure 3E). We then measured the telomerase
activity by TRAP assay in CD4T cells under the same treatment
conditions. As shown in Figure 3F, KML001-treated T cells
exhibited significantly decreased telomerase activity, suggesting
that KML001 causes telomere loss, not by inhibiting the hTERT
expression, but via inhibiting its enzymatic activity. Together,
these results indicate that KML001-induced telomeric DNA
damage and telomere erosion may cause cell apoptosis and T
cell loss, emphasizing the role of telomere integrity in securing
T cell survival.
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FIGURE 4 | KML001 impairs telomere integrity by inhibiting TRF2 protein expression. (A) Purified CD4T cells were treated with 5µM KML001 or DPBS control for
48 h, followed by western blotting to measure TRF2, TRF1, TIN2, POT1, TPP1, PAP1 protein expressions. Representative imaging and summary data of the western
blot are shown. NS, not significant. (B) Upper panel, HCV core protein was detected by fluorescence microscopy in Huh-7.5 hepatocytes transfected with HCV-JFH1
strain, but not in the mock transfected cells. Lower panel, TRF2 was inhibited in CD4T cells co-cultured with HCV+ Huh-7.5 cells compared to those incubated with
HCV− hepatocytes. GAPDH served as a loading control. (C) Upper panel, RT-PCR detection of HIV-RNA in SupT1 cells at day 3 and day 6 of HIV-1 infection. Lower
panel, western blotting of HIV-1 p24 and TRF2 expressions in SupT1 cells without (lane 1), or with low (lane 2) and high (lane 3) dose of HIV-1 infection. GAPDH
served as loading control. (D,E) Western blot analysis of p53 and Sirt6 expressions in CD4T cells exposed to KML001 (5µM) or DPBS control for 48 h. Summary
data were normalized to the DPBS control. (F) Western blot analysis of Sirt6 expression in TCR-activated CD4T cells by anti-CD3/CD28 stimulation (1µg/ml) and
exposed to KML001 (5µM) or DPBS treatment for 48 h. (G) Western blot analysis of p53, Sirt6, and TRF2 expressions in CD4T cells with or without KML001
treatment in the presence or absence of proteasomal inhibitor (MG-132).
KML001 Disrupts Telomere Integrity by
Inhibiting Shelterin Protein TRF2
Expression
Since telomeres are nucleoprotein complexes with a primary
function of capping the chromosome ends to prevent unwanted
DNAdamage, we hypothesized that disrupting telomere shelterin
may uncap chromosome ends, leading to telomere deprotection,
and telomere erosion. To test this possibility, we treated
human CD4T cells with 5µM KML001 or DPBS for 48 h,
followed by measuring the levels of shelterin proteins by western
blotting. As shown in Figure 4A, among the known human
shelterins (includes six polypeptides: TRF1, TRF2, RAP1, TIN2,
TPP1, and POT1), only TRF2 expression was significantly
inhibited (P = 0.0194) in CD4T cells following KML001
treatment. TPP1 (P = 0.1296) and TIN2 (P = 0.2230)—the
two proteins that can form a sub-complex with TRF2—were
also slightly inhibited, whereas TRF1 (P = 0.2550), RAP1 (P
= 0.5423), and POT1 (P = 0.2994) protein levels remained
unchanged by the treatment. These results are similar to our
findings in CD4T cells derived from chronic HCV or HIV
infection (38).
TRF2 appears to be central to telomere integrity in both the
setting of KML001 treatment and during viral infections such as
HCV and HIV. Since chronically HCV-infected patients often
have other co-morbidities that may interfere with TRF2 levels
and cause immune dysregulation, we examined the specific role
of HCV in inhibiting TRF2 expression. To this end, we incubated
naïve CD4T cells with Huh7.5 cells with or without HCV
infection, followed by measuring TRF2 protein expression. As
shown in Figure 4B, hepatocytes transfected with HCV-RNA for
48 h showed positive HCV core protein by immunofluorescence
staining, whereas cells with mock transfection exhibited negative
staining. RT-PCR showed HCV RNA in the supernatant of the
HCV-transfected cells, but not in media of mock-transfected cells
(data not shown). Importantly, similar to the findings in CD4T
cells derived from HCV patients or those treated with KML001,
TRF2 protein was suppressed in CD4T cells co-cultured with
HCV+ Huh-7.5 cells compared to those incubated with HCV−
Huh-7.5 hepatocytes, suggesting that HCV, like KML001, can
inhibit TRF2 expression.
Also, we found that TRF2 is inhibited, at the
posttranscriptional level, in CD4T cells derived from HIV-
infected individuals, we next examined the specific role of HIV in
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inhibiting TRF2 expression in the absence of other co-founding
factors. To this end, we established an in vitro HIV-1 T cell
culture system by employing a pNL4-3 plasmid (from NIH AIDS
Reagent Program) that contains a full-length HIV-1 viral genome
(45). Culture supernatants containing 1∼5 × 106 HIV-1 virions
fromHEK293T (human embryonic kidney 293 cells transformed
with SV40 large T antigen, purchased from the American Type
Culture Collection) cells transfected with pNL4-3 plasmid were
employed to infect SupT1 (a human CD4T cell line derived from
NIH AIDS Reagent Program) using the spinoculation method
(37). As shown in Figure 4C, HIV-RNA and p24 antigen were
detected by RT-PCR and western blot in HIV-infected SupT1
cells in a dose-dependent manner, but not in uninfected cells.
Importantly, compared to the uninfected control (lane 1), HIV-
infected cells (lane 2 and 3) exhibited a reduced TRF2 expression
at day 3 and day 6 after HIV-1 infection. In conjunction with
telomeric DDR and cell apoptosis, these results suggest that
TRF2 protein is inhibited in CD4T cells by viral infection that is
associated with the DDR-mediated cell apoptosis.
KML001 Inhibits Shelterin TRF2 via the p53
and Sirt6-Mediated, Ubiquitin-Dependent
Proteolysis
The mechanisms underlying TRF2 posttranscriptional inhibition
remain unclear. We have recently shown that ubiquitin-
mediated proteasome-degradation plays a key role in TRF2
regulation in CD4T cells during HCV infection (38). In
fibroblasts, the stability of TRF2 protein is also regulated
via a p53-induced E3 ubiquitin ligase (46). Notably, p53
itself is regulated by proteasomal degradation in muscle
cells (47). We thus hypothesized that this mechanism may
also occur in KML001-treated T lymphocytes as a means of
regulating TRF2 levels. To investigate the potential involvement
of p53-dependent proteolysis in TRF2 degradation, we
treated human CD4T cells with 5µM KML001 or DPBS
for 48 h, followed by western blotting for p53 levels. As
shown in Figure 4D, p53 protein levels were significantly
upregulated by the KML001 treatment, indicating a
strong DDR.
Additionally, a recent study indicates that the deacetylase Sirt6
specifically interacts with TRF2 and promotes its degradation via
the ubiquitin-dependent proteolysis in response to DNA damage
in fibroblasts (48). We thus examined Sirt6 expression and
found a significant upregulation of its protein levels in KML001-
treated CD4T cells (Figure 4E); Also, Sirt6 upregulation was
demonstrated in TCR-activated CD4T cells exposed to the
KML001 treatment (Figure 4F), suggesting that acetylation of
TRF2 may also play a role in regulating TRF2 protein stability
in T lymphocytes.
We further examined whether the protein degradation
machinery would contribute to the observed TRF2 protein
inhibition. To this end, we treated CD4T cells with or
without KML001 in the presence and absence of a proteasome
inhibitor (MG132), which can prevent proteolysis process.
Indeed, CD4T cells exposed to KML001 exhibited an increase
in p53 and Sirt6 expression, along with the decrease of
TRF2 level (compare Figure 4G lane 1 and 2). While MG132
treatment further increased p53 and Sirt6 levels (Figure 4G
lane 1 and 3), additional KML001 did not further increase
their expressions (Figure 4G lane 2 and 4, likely due to test
saturation), but the level of TRF2 appeared further decreased by
the treatment. These results demonstrate that KML001 triggers
telomeric DDR by suppressing shelterin TRF2 via promoting its
protein degradation, likely through the p53 and Sirt6-mediated,
ubiquitin-dependent proteolysis.
KML001 Triggers Topological DDR in T
Cells With Dynamic Activation and
Depletion of ATM Kinase
How KML001 triggers telomeric DNA damage that remains
unrepaired has been rather unclear. The intertwined, helical
structure of two complementary DNA strands is a unique
feature of chromosomes that can cause DNA entanglements
during genetic transactions, but topoisomerases can resolve these
topological problems to ensure normal genetic activity and
cell function (49). While catalytic inhibition of topoisomerase
has been exploited to kill bacterial or cancer cells (50), the
role of topoisomerases in reprogramming telomeric DDR and
remodeling T cell functions remains largely unknown. Recently,
we have discovered that the expressions and activities of Top1 as
well as Top2a were significantly inhibited in CD4T cells derived
from chronically HCV, HBV, or HIV-infected individuals, leading
to topological DNA damage, cell apoptosis, and ultimately,
alterations in T cell homeostasis (unpublished data). Also, it has
been shown that TRF2 can protect telomeres against topological
DNA damage by recruiting Top2a and its binding partner Apollo
(a member of the metallo-β-lactamase family that is required
for telomere integrity in S phase) during replicative stress (22).
To further investigate the mechanisms involved in KML001-
induced DNA damage, we examined Top1 as well as Top2a levels
(only expressed in activated T cells) in CD4T cells exposed to
KML001 for 48 h without or with anti-CD3/CD28 stimulation.
As shown in Figure 5A, along with the inhibition of TRF2 (but
not TRF1), the levels of Top1 and Top2a (but not Apollo)
were significantly inhibited. These findings suggest that Top1/2a-
mediated topological problems may involve in modulating T cell
telomeric DNA damage.
To gain insight into the cause and consequence of telomeric
DDR, we further explored the DNA repair machineries in CD4T
cells exposed to KML001. A major sensor of DNA-DSB is the
MRN complex (MRE11, RAD50, and NBS1), which subsequently
recruits the protein kinase ATM, an enzyme critically involved
in regulating DNA repair for cell survival. We thus examined
the ATM signaling pathway in KML-treated T cells. As shown in
Figure 5B, DNA-DSB sensor MRE11, but not RAD50 or NBS1,
was significantly inhibited in CD4T cells exposed to KML001.
In addition, ATM expression and phosphorylation (pATM) were
markedly suppressed in T cells with the KML001 treatment
for 48 h.
Since accumulation of DNA damage usually activates the
protein kinase ATM, which is in contrast with our findings of
ATM deficiency, we examined the kinetics of ATM expression
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FIGURE 5 | KML001 triggers topological DDR in CD4T cells with dynamic activation and deficiency of ATM kinase. CD4T cells were purified from HS and cultured in
the presence or absence of KML001 for indicated time, followed by immunoblotting or confocal microscopic analysis. (A) Representative imaging and summary data
of western blot analysis of TRF2, TRF1, and Top1 in CD4T cells exposed to 5µM KML001 or DPBS control for 48 h. Actin served as loading control. Since Top2a is
only expressed in TCR-activated cells, Top2a and Apollo expressions were measured in CD4T cells exposed to anti-CD3/CD28 stimulation (1µg/ml) and 5µM
KML001 or DPBS treatment for 48 h. GAPDH served as loading control. (B) Representative imaging and summary data of western blot analysis of MRE11, RAD50,
NBS1, ATM, and pATM expressions in CD4T cells exposed to 5µM KML001 or DPBS control for 48 h. (C) Western blot analysis of dynamic alterations in ATM and
pATM expressions in CD4T cells treated with 5µM KML001 or DPBS control for 3, 6, 12, 24, and 48 h. (D,E) Representative imaging of confocal microscopic
examination of co-localization of Ku70 and TRF1, as well as RAD51 and TRF1 in CD4T cells, treated with KML001 or DPBS for 48 h. (F) TOP1cc detected in genomic
DNA isolated from CD4T cells treated with or without TCR stimulation and KML001 treatment. (G) Representative imaging of confocal microscopic examination of
co-localization of TOP1cc and TRF1 in CD4T cells treated with KML001 or DPBS control.
and activation at different time-points following the KML001
treatment. As shown in Figure 5C, ATM and pATM were
upregulated in the early phase (3∼6 h), and then downregulated
in the late phase (24∼48 h), after KML001 treatment, reflecting a
dynamic alteration (early activation followed by depletion) of this
DNA repair kinase in the process of DDR in T cells. These results
are in line with our findings that insufficiency of ATM and TRF2
promotes CD4T cell loss in chronic HCV infection (36, 38) and
in latent HIV infection (unpublished data).
KML001 Induces TOP1cc Accumulation to
Prevent DNA Repair Molecule Recruitment
to the DNA Damage Sites
We have recently shown that the NHEJ pathway, rather than
the homologous recombination (HR) pathway of DNA repair,
participates in the ATM-mediated telomeric DNA damage repair
(unpublished data). However, how DSBs accumulate in cells
despite the presence of DNA repair proteins remains unknown. It
is well-known that Ku70 and Ku80 make up the Ku heterodimer,
which bind to DSB ends and is required for the NHEJ pathway of
DNA repair. It is also required for V(D)J recombination, which
utilizes the NHEJ pathway to promote antigen/antibody diversity
in the mammalian immune system. In addition to its role in
the NHEJ-mediated DNA repair, Ku is involved in telomere
maintenance (51). It has been reported that Ku70 deficient mice
exhibit premature aging (52), suggesting that Ku70 plays an
important role in longevity assurance and that reduced ability
to repair DNA DSB or maintain telomere integrity causes early
aging. To determine the role of the NHEJ pathway in repairing
KML001-induced telomeric DNA damage, we measured the
Ku70-dependent, dysfunctional TIF in CD4T cells exposed to
KML001 or DPBS for 48 h by confocal microscopy. Surprisingly,
we could not identify any Ku70/TRF1 co-localization in cells
treated with KML001 or DPBS control (Figure 5D), suggesting
that Ku70 failed to be recruited to the damaged telomeres.
We also examined possible involvement of the HR pathway in
KML001-induced DSB repair. Since RAD51 is involved in the
search for homology and strand pairing stages of the process (53,
54), we used confocal microscopy analysis for the RAD51/TRF1
co-localization in CD4T cells exposed to KML001 or DPBS for
48 h, and again, we did not find any difference between the two
treatments (Figure 5E).
Topoisomerases cleave and rapidly reseal one (type I) or two
(type II) DNA strands, generating a transient break through
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FIGURE 6 | CD4T cells derived from HCV or HIV-infected individuals are more vulnerable to telomere loss-mediated apoptosis. (A,B) Telomere length, measured was
by Flow-FISH, in CD4T cells isolated from HCV- or HIV-infected individuals and HS. Representative overlaid histograms and summary data with mean ± SEM and
p-values are shown. (C) Representative overlaid histogram and summary data of Flow-FISH analysis for telomere length in SupT1 cells infected with or without HIV-1
for 3 and 6 days. The mean fluorescence intensity (MFI) of telomere length in HIV-infected cells are normalized by those in uninfected cells. (D) PBMCs derived from
chronically HCV-infected individuals were treated with 5µM KML001 or DPBS control for 24 h, followed by flow cytometry analysis of Av expression in CD4+ T cells.
(E) PBMCs derived from latently HIV-infected individuals and HS were treated with 5µM KML001 or DPBS control for 24 h, followed by flow cytometry analysis of Av
expression in CD4+ T cells. Summary data with mean ± SEM (n = 8) and p-values are shown. (F) Dose-dependent induction of apoptotic death of CD4T cells
isolated from HCV- and HIV-infected individual and HS (n = 3 in each group) and exposed to varying concentrations of KML001 for 12 h. Representative dot plots of
CD4+ T cells at 2µM KML001 treatment and summary data of the dynamic changes of Av/7AAD levels in CD4+ T cells following varying concentrations of KML001
treatment are shown.
which topological modifications can occur (49). This catalytic
process is rather “dangerous” in that it generates an intermediate
in which the topoisomerase becomes covalently linked to
the terminus of nucleic acids through a phosphotyrosine
linkage, designated as the topoisomerase cleavage complex
(TOPcc). Failure to complete this catalytic cycle results
in trapping of topoisomerase on DNA termini, generating
protein-linked DNA breaks (PDB)—a frequent event that
causes cell death (55, 56). To determine if KML001-induced
telomeric DNA damage is due to TOPcc trapped in T cell
chromosomes, we measured TOP1cc in genomic DNA of
CD4T cells exposed to KML001 or DPBS control, using
a monoclonal antibody that specifically recognizes covalent
TOP1-DNA complexes, but not free TOP1 or DNA, by
immunoblotting (57). As shown in Figure 5F, a significant
amount of TOP1cc was detected in CD4T cells exposed to
KML001 for 48 h with or without TCR stimulation. These results
suggest that KML001-induced dysfunctional, senescent T cells
have topological aberrancies, i.e., TOP1 inhibition, leading to
TOP1cc accumulation.
Since KML001 induces cytotoxicity by trapping TOP1cc at
the TOP1-DNA covalent sites, which in turn interacts with
advancing replication or transcription complexes to generate
lethal DNA lesions, we further hypothesized that TOP1cc may
accumulate and occupy the DSB ends, preventing DNA repair
molecules to be recruited to the damaged sites of T cells. To
test this possibility, we examined the KML001-induced, TOP1cc-
mediated dysfunctional TIF using a monoclonal antibody that
specifically recognizes covalent TOP1-DNA complexes, but not
free TOP1 or DNA, by confocal microscopy (57). Indeed, we
found a significant increase of TOP1cc/TRF1-formed TIFs in
T cells exposed to KML001 compared to the DPBS control
(Figure 5G). Additionally, we found TOP1cc accumulation at
damaged telomeres in T cells treated with CPT (a specific TOP
1 inhibitor that can trigger topological DNA damage by inducing
TOP1cc accumulation at genomic DNA), whereas not in ATM
inhibitor (KU60019)-induced DNA damage, which does not
involve TOP1cc induction but occurs via the NHEJ pathway for
DNA damage repair (unpublished data). Taken together, these
results suggest that KML001 induces TOP1cc accumulation and
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trap at the DSB sites that may prevent DNA repair molecule
recruitment and inhibit DNA damage repair.
T Cells From Virus-Infected Individuals Are
More Vulnerable to Telomere Loss-Induced
Apoptotic Death
We have previously demonstrated that chronically HCV
and HIV-infected individuals exhibit T cell exhaustion and
senescence (1–4). Since the hallmark of T cell senescence is
telomere shortening, wemeasured telomere length in CD4T cells
isolated from HCV and HIV-infected individuals using Flow-
FISH. As shown in Figures 6A,B, similar to the CD4T cells
treated by KML001 (Figure 3D), telomere attrition was detected
in CD4T cells derived from both HCV and HIV-infected
individuals. This is consistent to our findings with HCV samples
reported previously (4, 38). We also measured the telomere
length in SupT1 cells with or without HIV-1 infection in vitro.
As shown in Figure 6C (representative overlaid histogram and
dynamic Flow-FISH data), T cells infected with HIV-1 at 3 days,
and particularly at 6 days, showed a clearly shortened telomere
length compared to uninfected cells. These data recapitulate the
findings with CD4T cells from HIV-infected patients.
Since KML001 can bind to telomeric DNA sequences, causing
telomere erosion and cell apoptosis (32), we also measured
apoptosis of CD4T cells derived from chronically HCV- and
HIV-infected individuals with or without KML001 treatment. As
shown in Figures 6D,E, HCV- and HIV-derived T cells were very
sensitive to the KML001-induced cell apoptosis. We next sought
to determine whether CD4T cells derived from chronically virus-
infected patients, which we have shown that they exhibit a
senescent state with an inhibited TRF2 and shortened telomeres,
are more sensitive to KML001-induced apoptosis. To this end,
we treated CD4T cells derived from virus-infected individuals
and age-matched HS with varying concentrations (0, 1, 2, 5,
10µM) of KML001 for a short period of time (12 h), followed
by flow cytometric analysis for Av/7AAD expression. As shown
in Figure 6F, compared to age-matched HS, HCV- and HIV-
derived T cells exhibited a relatively higher percentage of
apoptotic (Av+) and dead (7AAD+) cells following the KML001
treatment, in a dose-dependent manner, suggesting that they are
more vulnerable to the KML001-induced cell apoptotic death.
Taken together, our data reported here suggest that CD4T
cells from chronically virus-infected individuals are prone to
apoptosis and susceptible to telomere insult, likely due to the loss
of telomere integrity caused by the impairment of the telomere
sheltering (TRF2 protection), elongation (telomerase activity),
topology (Top1/2a disentanglement), and DNA repair (ATM
kinase) machineries.
DISCUSSION
During chronic viral infections, T cells exhibit a dynamic
over-activation and proliferation due to persistent antigenic
stimulation, followed by exhaustion and senescence, resulting in
immune dysfunctions that contribute to persistent infection and
vaccine non-responsiveness. Senescent T cells are characterized
by accelerated telomere erosion, which has two potential
outcomes: cell cycle arrest or cell apoptosis. Specifically, if
telomere attrition is mild to moderate, it will trigger cell
cycle arrest in order to give the cell a chance to repair the
DNA damage; however, if the telomere loss reaches a critical
point or DNA damage becomes irreparable, it will trigger
programmed cell death to get rid of cells harboring unhealthy
genetic transformations.
The mechanisms of telomere erosion and its role in
cell survival during genomic insult and cell stress remain
unclear. This is particularly true for T lymphocytes that
undergo self-renewal through proliferation upon antigenic
challenge to fight against invading pathogens. Notably, human
telomeres are programmed to lose 50∼100 base pairs (bp) per
population doubling (PD), resulting in replicative senescence
after ∼50 PDs (17). This shortening rate can reach ∼250
bp during viral infection, suggesting accelerated nucleolytic
attack or DNA damage on chromosome ends (17). Thus, we
speculate that senescence occurs when T cell chromosomes
experience significant telomere loss. However, telomere integrity
is preserved and safeguarded by multiple machineries (14–
18). Although the accidentally generated DNA-DSB can induce
DDR, natural chromosome ends (telomeres) do not trigger this
response. We now know that this suppression of DDR involves
the telomere protecting proteins (shelterin) that can inhibit
unwanted DDR (Figure 7A). Since the Nobel Prize-winning
discovery of the enzyme telomerase in 1984, identifying other
biological molecules that lengthen or shorten the protective caps
on the ends of chromosomes has been slow going. While it is
assumed that the relatively normal hTERT levels we found during
viral infection could compensate for telomere loss to prevent
cell crisis, the data presented in this study using CD4T cells
treated with KML001 or derived from chronic viral infection
argue against this notion, and suggest that telomerase is not
the only factor involved. Rather, the main events heralding the
end of the replicative life of human T cells are a failure of
several key players involved in protecting telomere integrity,
i.e., TRF2 deprotection and its associated loss of telomerase,
topoisomerase, and ATM kinase activities (Figure 7B). Since
telomeres are critical to maintain chromosome integrity and keys
to human health and longevity (15–17), the machineries involved
in telomere erosion are therefore major potential anti-aging
targets (Figure 7C).
TRF2 is a sequence-specific DNA binding protein that binds
to the duplex array of TTAGGG repeats at human telomeres and
protects chromosome ends from end-to-end fusion (19, 20). Loss
of TRF2 function leads to chromosomal abnormalities, cell cycle
arrest, and activation of the ATM–p53-mediated DDR pathway
(19, 20). The protective activity of TRF2 may be related to its
ability to form t loops, in which the G strand invades the duplex
part of the telomeres (19, 20). Based on our studies showing that
telomeres are not only shortened, but DNA is also damaged,
we believe that premature T cell aging is induced by a change
in the protected status (integrity) of telomeres rather than by a
pure loss of telomeric DNA. This hypothesis led us to explore
how TRF2 deprotection affects telomere integrity and cellular
fate in chronic viral infection. Remarkably, our results derived
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FIGURE 7 | A working model depicting the novel machineries involved in disrupting telomere integrity to induce T cell senescence and apoptosis during chronic viral
infection. (A) The telomere cap on the end of chromosomes unravels progressively with every cell division. The shelterin complex is required to protect telomeres
against undesired DNA damage response (DDR). (B) KML001 and chronic viral (HCV or HIV) infection can induce shelterin protein TRF2 degradation and inhibition of
Top2a, telomerase, and ATM enzyme activities, leading to telomeric DNA damage, T cell senescence and apoptosis. (C) Telomere shortening is a normal process in T
cells with human aging. While many factors drive human aging, viral infection accelerates telomere erosion, resulting in premature T cell aging and immune
senescence. This represents a novel molecular mechanism underlying the T cell dysfunction and immune (vaccine) non-responsiveness seen in patients with chronic
viral infection.
from KML001-treated CD4T cells are similar to the findings in
T cells during chronic viral (HCV, HIV) infection in that these
CD4T cells show a senescent status, characterized by telomere
erosion due to TRF2 inhibition via the p53- and Sirt6-mediated
ubiquitin degradation, and are more vulnerable to telomere
loss-mediated cell apoptosis. This is consistent with our recent
findings in chronic HCV infection, in which the expressions of
p53 and E3 ubiquitin ligase Siah-1a were significantly increased
in CD4T cells upon proteasome inhibition by MG132 treatment.
In addition, p21cip1, a p53 downstream cell cycle inhibitor and
cell senescence marker, was significantly upregulated by MG132
treatment in HCV-derived T cells, suggesting a p53-dependent,
Siah1a-mediated ubiquitin degradation of TRF2 in senescent
T cells during viral infection (38). Importantly, silencing TRF2
in healthy T cells by transfecting its siRNA results in telomeric
DNA damage. Conversely, reconstituting TRF2 in T cells from
virally infected individuals leads to a decrease in γH2AX level,
whereas overexpressing a truncated TRF2 mutant results in an
increase of γH2AX (38). Taken together, these findings suggest
that TRF2 sheltering is essential for protecting the telomere
from DNA damage and securing T cell survival. Our results in
which we show normal expression levels of TRF1 and telomerase
expression in CD4T cells exposed to KML001 and HCV or HIV
infection confirm the idea that TRF1 controls telomere dynamics
primarily by affecting the telomerase-mediated telomere
elongation (58, 59). Thus, TRF1 and TRF2 both act as negative
regulators of telomere length, but affect different aspects of
telomere dynamics.
The role of telomere uncapping in cell senescence is
incompletely understood. A recent study indicates that
replicative senescence is induced by partially deprotected
telomeres, which activate an ATM and topoisomerase-mediated
DDR without chromosomal end-to-end fusions (60). This
telomere deprotection response is functionally distinct from the
genomic DDR in that, unlike genomic DNA breaks, deprotected
telomeres do not contribute to the G2/M checkpoint and are
instead passed through cell division to induce p53-dependent G1
arrest in daughter cells (60). Telomere deprotection is therefore
an epigenetic signal passed between cell generations to ensure
that replication-dependent growth arrest occurs in stable diploid
G1 phase cells, before genomic instability can occur. Moreover,
TRF2 can reduce the senescence set-point, defined as telomere
length at senescence ranging from 7 to 4 kilobases (61). TRF2 can
protect critically short telomeres and repress chromosome-end
fusion, which explains the ability of TRF2 to delay senescence.
If genomic insult is persistent and critical, the cells will be
in crisis, requiring a bypass of senescence pathways through
loss of checkpoints and causing TRF2 uncapping and further
telomere shortening and spontaneous telomere fusion, resulting
in programmed cell death (apoptosis). On the other hand,
retroviral-mediated overexpression of TRF2 in several human
fibroblast cell lines results in an accelerated telomere shortening,
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likely through an enhanced 5′ exonucleolytic processing of
telomere ends by recruiting an exonuclease regardless of the
status of p53 or the p16-RB pathways; the cells remain alive,
however, without accelerating senescence (61). These studies
suggest that excess TRF2 can protect very short telomeres to
maintain cell viability and that this is the mechanism by which
TRF2 can extend the lifespan and alter the senescence set-point
of primary human cells.
Collectively, our findings support that replicative senescence
in human T cells is caused by a change in the status
of the telomeric complex, in particular TRF2 loss-mediated
telomeric DNA damage and failure to repair, rather than by
a purely telomerase-mediated loss of telomeric sequences. If
the senescence signal was a function of cell chromosome ends
lacking telomeric DNA altogether, TRF2 would not be expected
to repress this signal and alter the senescence set-point. One
possibility is that critically shortened telomeres in senescent
human cells can no longer bind sufficient TRF2 to achieve a
protective state, such as the t-loop. Alternatively, binding of
TRF2may facilitate the recruitment of other proteins required for
telomere protection and suppression of senescence. For instance,
TPP1 reduction has been shown to cause telomere attrition
and cellular senescence via Sirt1 deacetylase-mediated proteolysis
degradation (62). Intriguingly, we have recently reported that
the anti-aging molecule Sirt1 is upregulated in CD4T cells
via a decline in miRNA181a expression to balance DUSP6-
mediated cell senescence during chronic HCV infection (3, 4).
We find that while the mRNA level of TPP1 is upregulated,
its protein expression in CD4T cells is downregulated by
KML001 treatment, as well as by HCV infection (38). Notably,
TPP1 can directly interact with telomerase, whereas TRF2
can bind TIN2 and then TPP1 to form a sub-complex (38).
Whether the miRNA181a/Sirt1 axis plays a role in TPP1
posttranscriptional regulation and whether TRF2/TIN2/TPP1
fails to recruit telomerase at telomeres during viral infection is
under investigation in our laboratory.
This study has clinical relevance and potential applications:
first, our data showed that T cell apoptotic death during
chronic viral infection correlated with TRF2-mediated telomere
uncapping and its associated telomerase, topoisomerase, and
ATM kinase inhibition. Based on this, we propose that TRF2
inhibition is the main mechanism that limits cellular lifespan
upon bypass of senescence. Aging is a progressive mystery
involving a range of architects, but TRF2-mediated telomere
shortening has been associated with multiple age-related diseases
and thus we believe that we have to find ways to replenish
TRF2 and repair telomeres if we want to live healthy and
longer. Second, these findings might also offer a translational
opportunity for tumorigenesis, anti-cancer treatment, and
immunomodulation, since exacerbation of TRF2-mediated
telomere deprotection sensitizes cancer and immune cells
to telomere-targeting drugs, such as arsenic compounds.
Additionally, uncovering the telomere mystery can help us
understand how cells strike a balance between premature
aging and the uncontrolled cell growth of cancer, which is
very intriguing. Third, cell cycle arrest has been associated
with chronic infections in checkpoint-compromised cells
(63). Similarly, bone marrow failure and neurodegeneration
in individuals with telomere loss are frequent, which could
potentially be explained by cell progression arrest that results
from relatively unprotected telomeres (64, 65). Therefore,
TRF2-mediated telomere uncapping and the resulting telomere
loss-driven cell cycle arrest in the early stage of viral infections
may function as a double-edged sword, explaining both the
overwhelming cell death storm in acute infection, and the
immune tolerance or immunosuppression in chronic/persistent
infection; whereas lengthened and damaged telomeres are
associated with cell chromosomal rearrangement and tumors
(66). Thus, this study enhances our understanding of T
cell senescence, apoptosis, and functional dysregulation
during viral infection, and identifies novel targets to modify
telomeric shelterin, particularly TRF2-mediated telomeric DNA
damage and repair machineries, as a new strategy to prevent
chromosomal ends from unwanted DDR and to salvage cells
from crisis.
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